



Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Alexander Egle^{1,2} · Michael Steurer³ · Thomas Melchardt^{1,2} · Lukas Weiss^{1,2} · Franz Josef Gassner² · Nadja Zaborsky² · Roland Geisberger² · Kemal Catakovic² · Tanja Nicole Hartmann² · Lisa Pleyer^{1,2} · Daniela Voskova⁴ · Josef Thaler⁵ · Alois Lang⁶ · Michael Girschikofsky⁷ · Andreas Petzer⁸ · Richard Greil^{1,2}

Published online: 23 June 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Correction to: Annals of Hematology
<https://doi.org/10.1007/s00277-018-3380-z>

The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann.

The original article has been corrected.

The online version of the original article can be found at <https://doi.org/10.1007/s00277-018-3380-z>

✉ Richard Greil
r.greil@salk.at

¹ Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020 Salzburg, Austria

² Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria

³ Division of Hematology and Oncology, Laboratory for Molecular Genetics and Diagnostics, Innsbruck Medical University, Innsbruck, Austria

⁴ Centre for Hematology and Medical Oncology, Kepler University Hospital, Linz, Austria

⁵ Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria

⁶ Internal Medicine, Hospital, Feldkirch, Austria

⁷ Internal Medicine I (Hemostasis, Hematology and Stem Cell Transplantation and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria

⁸ Department for Internal Medicine IV, Hospital Barmherzige Schwestern Linz, Linz, Austria